Balyasny Asset Management
BNTC icon

Balyasny Asset Management’s Benitec Biopharma BNTC Stock Holding History

Balyasny Asset Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96M Buy
653,835
+2,277
+0.3% +$26.4K 0.01% 1207
2025
Q4 		$8.78M Buy
+651,558
New +$9.01M 0.01% 1090
2025
Q2 		– Sell
-2,816
Closed -$39.4K – 2846
2025
Q1 		$36.6K Buy
+2,816
New +$34.1K ﹤0.01% 2714

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Balyasny Asset Management's BNTC Position: Q1 2026 in Review

Balyasny Asset Management increased its Benitec Biopharma (BNTC) stake by 0.35% in Q1 2026, buying an estimated $26.4K and bringing the position to 653,835 shares worth $6.96M. The position accounts for 0.01% of the portfolio, ranked #1207.

Balyasny Asset Management first reported a position in BNTC in Q1 2025 and has held it in 3 quarters since. The position peaked at $8.78M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Balyasny Asset Management held 653,835 shares of Benitec Biopharma worth $6.96M as of Q1 2026.
  • Balyasny Asset Management bought 2,277 Benitec Biopharma shares in Q1 2026, an estimated $26.4K.
  • Benitec Biopharma made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1207 holding.
  • Balyasny Asset Management first reported a position in Benitec Biopharma in Q1 2025 and has held it in 3 quarters since.
  • Balyasny Asset Management's Benitec Biopharma position peaked at $8.78M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.